Severe Combined Immunodeficiency Clinical Trial
Official title:
The Determination of Genetic Basis Of Immunodeficiency
NCT number | NCT00055172 |
Other study ID # | 030105 |
Secondary ID | 03-H-0105 |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | April 5, 2004 |
This study will examine the role of hereditary factors in different forms of severe combined immunodeficiency (SCID). Patients with immunodeficiencies may be eligible for this study. Candidates include: - Patients with diminished numbers of T cells or NK cells or both, or - Patients with normal T cell and NK cell numbers but diminished T cell, B cell, or NK cell function. Relatives of patients will also be studied. Participants will have blood samples collected for genetic analysis in studies related to SCID at the National Institutes of Health and other institutions.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months to 99 Years |
Eligibility | - INCLUSION CRITERIA: Index cases to be included are those with diminished numbers of T cells and/or NK cells and/or B cells or other immune cells or those who have normal numbers of T cell, B cells, NK cells and other immune cells but diminished function of one or more immune cells. Relatives of affected individuals may also be studied - Patients (index cases): 6 months of age and older - Siblings: 6 months of age and older - Non-sibling relatives (biological parent, aunt, uncle or grandparent): 18 years or older EXCLUSION CRITERIA: - Patients with a known diagnosis - Patients with a particular immunological phenotype that is not of interest to the research conducted under this study. - Pregnancy or lactation - Adults with current decisional impairment |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, McBride OW, Leonard WJ. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 1993 Apr 9;73(1):147-57. doi: 10.1016/0092-8674(93)90167-o. — View Citation
Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet. 1998 Dec;20(4):394-7. doi: 10.1038/3877. — View Citation
Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, Migone TS, Noguchi M, Markert ML, Buckley RH, O'Shea JJ, Leonard WJ. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science. 1995 Nov 3;270(5237):797-800. doi: 10.1126/science.270.5237.797. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To identify forms of inherited immunodeficiency resulting from mutation of yc dependent cytokines, components of their receptors, or signaling molecules in their pathways | In an effort to determine the cause of the immunodeficiency, we will perform studies that may include but not be limited to evaluating the levels of expression of protein and/or mRNA, obtaining DNA sequence data, performing epigenetic studies, and evaluating biological function using cellular, biochemical, or other molecular studies. | ongoing |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00006335 -
Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID
|
N/A | |
Not yet recruiting |
NCT02231983 -
Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China
|
N/A | |
Active, not recruiting |
NCT03597594 -
Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)
|
Phase 1/Phase 2 | |
Completed |
NCT00000603 -
Cord Blood Stem Cell Transplantation Study (COBLT)
|
Phase 2 | |
Completed |
NCT00001255 -
Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study
|
N/A | |
Recruiting |
NCT05651113 -
The Experience of Screening for SCID
|
||
Completed |
NCT00794508 -
MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID
|
Phase 2 | |
Recruiting |
NCT03538899 -
Autologous Gene Therapy for Artemis-Deficient SCID
|
Phase 1/Phase 2 | |
Recruiting |
NCT05298930 -
Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT01821781 -
Immune Disorder HSCT Protocol
|
Phase 2 | |
Completed |
NCT00845416 -
Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population
|
N/A | |
Terminated |
NCT00006054 -
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
|
N/A | |
Completed |
NCT03878069 -
Registry Study of Revcovi Treatment in Patients With ADA-SCID
|
||
Recruiting |
NCT01019876 -
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
|
Phase 2/Phase 3 | |
Completed |
NCT03513328 -
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02177760 -
Sirolimus Prophylaxis for aGVHD in TME SCID
|
Phase 2 | |
Recruiting |
NCT00695279 -
Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products
|
||
Completed |
NCT01420627 -
EZN-2279 in Patients With ADA-SCID
|
Phase 3 | |
Terminated |
NCT02127892 -
SCID Bu/Flu/ATG Study With T Cell Depletion
|
Phase 1/Phase 2 | |
Completed |
NCT04246840 -
Study Through Imaging of Visceral Lymphoid Organs in Patients With SCID Who Have Recieved Bone Marrow Allograft
|